Please use this identifier to cite or link to this item:
|Title:||Personalized Chemosensitivity Assays for Mesothelioma: Are They Worth the Effort?|
|Authors:||John, Thomas;Chia, Puey Ling|
|Affiliation:||Faculty of Medicine, University of Melbourne, Melbourne, Victoria, Australia|
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia
Department of Medical Oncology, Olivia Newton John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia
|Citation:||Clinical cancer research : an official journal of the American Association for Cancer Research 2018; 24(7): 1513-1515|
|Abstract:||Cell lines formed from an individual's tumor can be used to predict response to specific therapies and determine genomic predictors. For mesothelioma, where chemotherapy remains the backbone of current therapeutic paradigms, such assays could be used to treat patients with the most effective agents specific to their "chemical profile." Clin Cancer Res; 24(7); 1513-5. ©2018 AACRSee related article by Schunselaar et al., p. 1761.|
Research Support, Non-U.S. Gov't
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.